Alcobra Ltd. (ADHD) Receives Average Recommendation of “Hold” from Analysts
Alcobra Ltd. (NASDAQ:ADHD) has earned a consensus rating of “Hold” from the eleven analysts that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $2.02.
Several equities analysts have recently issued reports on the company. Roth Capital set a $4.00 price objective on Alcobra and gave the stock a “buy” rating in a research report on Wednesday, May 31st. Jefferies Group LLC reiterated a “hold” rating and set a $1.25 price objective on shares of Alcobra in a research report on Friday, March 31st. Zacks Investment Research downgraded Alcobra from a “buy” rating to a “hold” rating in a research report on Tuesday, March 7th. Cantor Fitzgerald reissued a “hold” rating and set a $1.00 target price on shares of Alcobra in a report on Tuesday, March 28th. Finally, ValuEngine cut Alcobra from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.
Alcobra (ADHD) opened at 1.15 on Tuesday. The stock’s 50 day moving average price is $1.16 and its 200-day moving average price is $1.36. The stock’s market capitalization is $31.70 million. Alcobra has a 52 week low of $0.83 and a 52 week high of $5.36.
Alcobra (NASDAQ:ADHD) last issued its quarterly earnings data on Tuesday, May 30th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. Equities research analysts expect that Alcobra will post ($0.64) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/06/27/alcobra-ltd-adhd-receives-average-recommendation-of-hold-from-analysts.html.
Large investors have recently made changes to their positions in the company. Citadel Advisors LLC boosted its stake in shares of Alcobra by 7,251.0% in the first quarter. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 101,514 shares during the last quarter. Morgan Stanley boosted its stake in shares of Alcobra by 3,267.0% in the first quarter. Morgan Stanley now owns 472,495 shares of the biotechnology company’s stock valued at $539,000 after buying an additional 458,462 shares during the last quarter. Royce & Associates LP boosted its stake in shares of Alcobra by 15.5% in the first quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company’s stock valued at $849,000 after buying an additional 100,000 shares during the last quarter. Worth Venture Partners LLC purchased a new stake in shares of Alcobra during the first quarter valued at approximately $229,000. Finally, Franklin Resources Inc. boosted its stake in shares of Alcobra by 12.8% in the fourth quarter. Franklin Resources Inc. now owns 4,477,500 shares of the biotechnology company’s stock valued at $9,403,000 after buying an additional 509,065 shares during the last quarter. 38.18% of the stock is currently owned by hedge funds and other institutional investors.
Alcobra Company Profile
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.